epirubicin/cyclophosphamide
Phase 3Small molecule
epirubicin/cyclophosphamide is one of 41 small molecule programs targeting Breast Cancer. It is currently in Phase 3.
1
Indications
4
Total Trials
2
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1epirubicin/cyclophosphamide
EEuropean Organisation for Research and Treatment of Cancer - EORTC
Phase 3
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Zolymbus
AbbViePreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Spravato
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer4 trials
Adjuvant Palbociclib in Elderly Patients With Breast Cancer
Active, not recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT03609047·366 enrolled
Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT05834582·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for epirubicin/cyclophosphamide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details